Current filters:


Asia-Pacific region macular degeneration market to see modest growth; report

Asia-Pacific region macular degeneration market to see modest growth; report


Due to the absence of promising products in the pipeline or expected new drug launches, the macular degeneration…

Asia-PacificBayerEyleaLucentisMacugenMarkets & MarketingNovartisOphthalmicsPfizerPharmaceuticalRegeneronRoche

BIA warns that UK government pricing proposals would damage UK biotech


The BioIndustry Association (BIA), the UK trade association for the innovative biotechnology sector,…


Strong uptake of Regeneron/Bayer wet AMD drug Eylea in USA, but Avastin still leads


The majority of wet age-related macular degeneration (AMD) patients are administered their first intravitreal…

AllerganAvastinBayerBiotechnologyEyleaFovistaLucentisMarkets & MarketingNorth AmericaOphthalmicsOphthotechPharmaceuticalRegeneronRoche

Avastin remains preferred DME therapy, despite Lucentis extended label in USA


Despite the approval of Swiss drug major Roche (ROG: SIX) subsidiary Genentech's Lucentis (ranibizumab…

AvastinBayerBiotechnologyEyleaGenentechLucentisMarkets & MarketingNorth AmericaOphthalmicsPharmaceuticalRegeneronRoche

Trial and uptake of Regeneron's Eylea continues to rise among US retinal specialists; report


After six months on the market, 76% of retinal specialists in the USA have prescribed US biotech firm…

AvastinBayerEyleaLucentisMarkets & MarketingNorth AmericaOphthalmicsPharmaceuticalRegeneronRoche

Regeneron and Bayer’s Eylea backed by thought leaders for DME


Based on clinical data and the opinions of interviewed thought leaders by health care advisory firm Decision…

AllerganBayerEyleaLucentisMarkets & MarketingNorth AmericaOphthalmicsOzurdexPharmaceuticalRegeneron

AMD and diabetic retinopathy drugs market to reach $5.08 billion by 2014, says Visiongain


The market for age-related macular degeneration (AMD) and diabetic retinopathy (DR) drugs will reach…

BayerEyleaLucentisMarkets & MarketingOphthalmicsPharmaceuticalRegeneronRoche

Ph III studies show Bayer and Regeneron VEGF Trap-Eye in wet AMD meets primary endpoints versus Lucentis


German drug major Bayer (BAY: DE) and US partner Regeneron Pharmaceuticals (Nasdaq: REGN) reveal that,…

afliberceptBayerLucentisNovartisOpthalmicsPharmaceuticalRegeneronResearchRocheVEGF Trap-Eye

Back to top